Abstract
Objective: Low water solubility, high systemic toxicity and insignificant cellular uptake have limited efficient clinical applications of the anti-tumor agent Paclitaxel (PTX). To overcome these limitations, a Novel Nanostructured Lipid Carrier (NLC) modified with Folic Acid (FA) and polyethylene glycol (PEG) was prepared by emulsion solvent evaporation method using cholesterol, α-tocopherol, lecithin and Poloxamer. A partial factorial design was applied to determine the appropriate levels of variables for optimized formulation. Formulations were evaluated for Particle Size (PS), Zeta Potential (ZP), Entrapment Efficiency (EE), and release efficiency (RE72%). FA- and PEGconjugated octadecylamine (FA-ODA and PEG-ODA) were synthesized and confirmed by FTIR and H-NMR and incorporated either alone or in combination with the optimized formulation whose properties were also evaluated. PTX-loaded optimized, targeted, pegylated, targeted/pegylated NLCs, pure PTX, and Anzatax® along with their respective controls were selected for toxicity evaluation on human breast cancer cell line, MCF-7, using MTT assay.
Methods: PS, ZP, EE%, and RE72% of the optimized formulation were 154.6 nm, -16.5 mv, 79.1% and 49.3%, respectively. Incorporation of α-tocopherol as the liquid lipid allowed for more efficient drug encapsulation, PS reduction, enhanced stability and sustained-release of the drug. Cytotoxicity of PTX-loaded NLCs modified with both FA-ODA and PEG-ODA was significantly enhanced compared to that of free PTX and other drug-loaded modified NLCs.
Results and Conclusion: The results suggest that preparation of NLCs with synthesized conjugates might be a promising candidate for drug delivery of PTX to the cancerous cells and has a great potential as a carrier for tumor targeting in breast cancer.
Keywords: Nanostructured lipid carriers, polyethylen glycol, folic acid, MCF-7, cell toxicity, paclitaxel.
Current Drug Delivery
Title:Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity
Volume: 14 Issue: 8
Author(s): Mahboubeh Rezazadeh, Jaber Emami*, Farshid Hassanzadeh, Hojjat Sadeghi, Mahboubeh Rostami and Hamid Mohammadkhani
Affiliation:
- Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences and Isfahan Pharmaceutical Research Center, Isfahan University of Medical Sciences, Isfahan,Iran
Keywords: Nanostructured lipid carriers, polyethylen glycol, folic acid, MCF-7, cell toxicity, paclitaxel.
Abstract: Objective: Low water solubility, high systemic toxicity and insignificant cellular uptake have limited efficient clinical applications of the anti-tumor agent Paclitaxel (PTX). To overcome these limitations, a Novel Nanostructured Lipid Carrier (NLC) modified with Folic Acid (FA) and polyethylene glycol (PEG) was prepared by emulsion solvent evaporation method using cholesterol, α-tocopherol, lecithin and Poloxamer. A partial factorial design was applied to determine the appropriate levels of variables for optimized formulation. Formulations were evaluated for Particle Size (PS), Zeta Potential (ZP), Entrapment Efficiency (EE), and release efficiency (RE72%). FA- and PEGconjugated octadecylamine (FA-ODA and PEG-ODA) were synthesized and confirmed by FTIR and H-NMR and incorporated either alone or in combination with the optimized formulation whose properties were also evaluated. PTX-loaded optimized, targeted, pegylated, targeted/pegylated NLCs, pure PTX, and Anzatax® along with their respective controls were selected for toxicity evaluation on human breast cancer cell line, MCF-7, using MTT assay.
Methods: PS, ZP, EE%, and RE72% of the optimized formulation were 154.6 nm, -16.5 mv, 79.1% and 49.3%, respectively. Incorporation of α-tocopherol as the liquid lipid allowed for more efficient drug encapsulation, PS reduction, enhanced stability and sustained-release of the drug. Cytotoxicity of PTX-loaded NLCs modified with both FA-ODA and PEG-ODA was significantly enhanced compared to that of free PTX and other drug-loaded modified NLCs.
Results and Conclusion: The results suggest that preparation of NLCs with synthesized conjugates might be a promising candidate for drug delivery of PTX to the cancerous cells and has a great potential as a carrier for tumor targeting in breast cancer.
Export Options
About this article
Cite this article as:
Rezazadeh Mahboubeh, Emami Jaber *, Hassanzadeh Farshid , Sadeghi Hojjat , Rostami Mahboubeh and Mohammadkhani Hamid , Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity, Current Drug Delivery 2017; 14 (8) . https://dx.doi.org/10.2174/1567201814666170503143646
DOI https://dx.doi.org/10.2174/1567201814666170503143646 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanoemulsions in cancer therapy
Solid tumors are characterized by leaky vascular structure, defective angiogenesis and high interstitial fluid load, providing opportunities for nanoparticles to preferentially exudate and be retained in tumors. This phenomenon is commonly referred to as the enhanced permeability and retention (EPR) effect, which is considered to be an important reason why ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Antimicrobial Activity of Some Novel Substituted 3-(Thiophen-2-yl)pyrazole-based Heterocycles
Letters in Drug Design & Discovery Development of In Vitro Co-Culture Model in Anti-Cancer Drug Development Cascade
Combinatorial Chemistry & High Throughput Screening The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Editorial
Current Medical Imaging Overview of Angiogenesis and the use of Bevacizumab in Patients with Malignant Gliomas
Current Signal Transduction Therapy Ion Transporters in Brain Tumors
Current Medicinal Chemistry Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Novel Reverse-Phase High-Performance Liquid Chromatography (RPHPLC) Method for the Quantification of Apigenin in Ocimum Basilicum Linn Seeds (Tukmaria)
Current Analytical Chemistry A Review of Bisindolylmethane as an Important Scaffold for Drug Discovery
Current Medicinal Chemistry Inhibition of Growth of Esophageal Cancer by Alantolactone via Wnt/β- Catenin Signaling
Anti-Cancer Agents in Medicinal Chemistry Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets Aptamer-based Advances in Skin Cancer Research
Current Medicinal Chemistry Tumor Targeting with Apatinib-loaded Nanoparticles and Sonodynamic Combined Therapy
Current Molecular Medicine Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy
Current Medicinal Chemistry Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders
Current Neuropharmacology Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology Nanocarriers for Effective Brain Drug Delivery
Current Topics in Medicinal Chemistry Neuroendocrine Tumors of the Lung: Hystological Classification, Diagnosis, Traditional and New Therapeutic Approaches
Current Medicinal Chemistry